Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomerica (BMRA) Cost of Revenue (2016 - 2025)

Biomerica's Cost of Revenue history spans 16 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 3.74% year-over-year to $1.2 million; the TTM value through Nov 2025 reached $4.2 million, down 15.59%, while the annual FY2025 figure was $4.8 million, 0.19% changed from the prior year.
  • Cost of Revenue for Q4 2025 was $1.2 million at Biomerica, up from $956000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $6.0 million in Q1 2022 and bottomed at $956000.0 in Q3 2025.
  • The 5-year median for Cost of Revenue is $1.2 million (2024), against an average of $1.9 million.
  • The largest annual shift saw Cost of Revenue surged 327.89% in 2022 before it plummeted 83.45% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $3.9 million in 2021, then tumbled by 70.84% to $1.1 million in 2022, then increased by 9.73% to $1.2 million in 2023, then fell by 3.06% to $1.2 million in 2024, then decreased by 3.74% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for BMRA's Cost of Revenue are $1.2 million (Q4 2025), $956000.0 (Q3 2025), and $993000.0 (Q2 2025).